1. Liang J, Williams DR, Miller DT (1997) Supernormal vision and high-resolution retinal imaging through adaptive optics. J Opt Soc Am A Opt Image Sci Vis 14: 2884–2892.
2. Roorda A, Williams DR (1999) The arrangement of the three cone classes in the living human eye. Nature 397: 520–522.
3. Roorda A, Williams DR (2002) Optical fiber properties of individual human cones. J Vis 2: 404–412.
4. Roorda A, Romero-Borja F, Donnelly W Iii, Queener H, Hebert T, et al. (2002) Adaptive optics scanning laser ophthalmoscopy. Opt Express 10: 405–412.
5. Pallikaris A, Williams DR, Hofer H (2003) The reflectance of single cones in the living human eye. Invest Ophthalmol Vis Sci 44: 4580–4592.
6. Choi SS, Doble N, Hardy JL, Jones SM, Keltner JL, Olivier SS, Werner JS (2006) In vivo imaging of the photoreceptor mosaic in retinal dystrophies and correlations with visual function. Invest Ophthalmol Vis Sci 47:2080–2092
7. Tojo N, Nakamura T, Fuchizawa C, Oiwake T, Hayashi A (2013) Adaptive optics fundus images of cone photoreceptors in the macula of patients with retinitis pigmentosa. Clin Ophthalmol 7:203–210
8. Akiyama E, Sugiyama S, Matsuzawa Y, Konishi M, Suzuki H, Nozaki T, et al. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol.
9. Bennett AG, Rudnicka AR, Edgar DF (1994) Improvements on Littmann's method of determining the size of retinal features by fundus photography. Graefes Arch Clin Exp Ophthalmol 1994; 232:361-367. https://doi.org/10.1007/BF00175988
10. Ichiyama Y, Sawada T, Ito Y et al (2017) Optical coherence tomography angiography reveals blood flow in choroidal neovascular membrane in remission phase of neovascular age-related macular degeneration. Retina 37:724-730. https://doi.org/10.1097/IAE.0000000000001576
11. Ohtsu N (1979) A threshold selection method from gray level histograms. IEEE Trans Sys Man Cyber 9:62-66. https://doi.org/10.1109/TSMC.1979.4310076
12. Sadda SR, Guymer R, Holz FG et al (2018) Consensus definition for atrophy associated with age-related macular degeneration on OCT: Classification of atrophy report 3. Ophthalmology 125:537-548. https://doi.org/10.1016/j.ophtha.2017.09.028
13. Gune S, Abdelfattah NS, Karamat A et al (2020) Spectral-domain OCT-based prevalence and progression of macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology 127:523-532. https://doi.org/10.1016/j.ophtha.2019.09.030
14. Duncan JL, Zhang Y, Gandhi J, Nakanishi C, Othman M, Branham KE, Swaroop A, Roorda A (2007) High-resolution imaging with adaptive optics in patients with inherited retinal degeneration. Invest Ophthalmol Vis Sci 48(7):3283–3291
15. Georgiou M, Kalitzeos A, Patterson EJ, Dubra A, Carroll J, Michaelides M (2017) Adaptive optics imaging of inherited retinal diseases. Br J Ophthalmol 15. https://doi.org/10.1136/ bjophthalmol-2017-311328.
16. Sun LW, Johnson RD, Langlo CS, Cooper RF, Razeen MM, Russillo MC, Dubra A, Connor TB Jr, Han DP, Pennesi ME, Kay CN, Weinberg DV, Stepien KE, Carroll J (2016) Assessing photo- receptor structure in retinitis pigmentosa and usher syndrome. Invest Ophthalmol Vis Sci 57(6):2428–2442. https://doi.org/10. 1167/iovs.15-18246
17. Ratnam K, Carroll J, Porco TC, Duncan JL, Roorda A (2013) Relationship between foveal cone structure and clinical measures of visual function in patients with inherited retinal degenerations. Invest Ophthalmol Vis Sci 54(8):5836–5847. https://doi.org/10. 1167/iovs.13-12557
18. Ijima H (2012) Correlation between visual sensitivity loss and years affected for eyes with retinitis pigmentosa. Jpn J Ophthalmol 56(3): 224–229
19. Rangaswamy NV, Patel HM, Locke KG, Hood DC, Birch DG (2010) A comparison of visual field sensitivity to photoreceptor thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci 51(8):4213–4219. https://doi.org/10.1167/iovs.09-4945
20. Makiyama Y, Ooto S, Hangai M, Takayama K, Uji A, Oishi A, Ogino K, Nakagawa S, Yoshimura N (2013) Macular cone abnor- malities in retinitis pigmentosa with preserved central vision using adaptive optics scanning laser ophthalmoscopy. PLoS One 8(11): e79447 – e72013. https://doi.org/10.1371/journal.pone.0079447. eCollection
21. Cursio CA, Sloan KR, Kalina RE, Hendrickson AE (1990) Human photoreceptor topography. J Comp Neurol 292:497–523
22. Marc RE, Jones BW, Watt CB, Strettoi E (2003) Neural remodeling in retinal degeneration. Prog Retin Eye Res 22:607–655
23. Wolsley CJ, Silvestri O’NJ, Saunders KJ, Anderson RS (2009) The association between multifocal electroretinograms and OCT retinal thickness in retinitis pigmentosa patients with good visual acuity. Eye 23:1524–1531
24. Stepien KE, Han DP, Schell J et al., “Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss,” Transactions of American Ophthalmological Society, vol.107, pp.28-33, 2009.
25. Debellemanière G, Flores M, Tumahai P et al., “Assessment of parafoveal cone density in patients taking hydroxychloroquine in the absence of clinically documented retinal toxicity,” Acta Ophthalmologica, vol.93, no.7, pp.e534-540, 2015.
26. Jorge A, Ung C, Young LH et al., “Hydroxychloroquine retinopathy - implications of research advances for rheumatology care,” Nature Reviews. Rheumatology, vol.14, no.12, pp.693-703, 2018.
27. Browning DJ, Yokogawa N, Greenberg PB et al., “Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines,” American Journal of Ophthalmology, vol.219, pp.101-106, 2020.
28. Melles RB, Marmor MF., “Pericentral retinopathy and racial differences in hydroxychloroquine toxicity,” Ophthalmology, vol.122, no.1, pp.110-116, 2015.
29. Ozawa H, Ueno S, Ohno-Tanaka A et al., “Ocular findings in Japanese patients with hydroxychloroquine retinopathy developing within 3 years of treatment,” Japanese Journal of Ophthalmology, vol.65, no.4, pp.472-481, 2021.
30. Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitra D, Ganz P. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol. 2006;101:545–8.
31. Hamburg NM, Vita JA. Endothelial dysfunction in atheroscle- rosis: mechanisms of impaired nitric oxide bioactivity. In: Los- calzo J, editor. Molecular mechanisms of atherosclerosis. London: Taylor and Francis; 2006. p. 95–110.
32. Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation. 2008;117:2467–74.
33. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149–60.
34. Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. 2010;31:1142–8. doi:10.1093/eurheartj/ ehq010 (Epub 2010 Feb 24).
35. Connell PP, Keane PA, O’Neill EC, Altaie RW, Loane E, Neelam K, et al. Risk factors for age-related maculopathy. J Ophthalmol. 2009;2009:360764. doi:10.1155/2009/360764.
36. Snow KK, Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol. 1999;6:125–43.
37. Machalin´ska A, Kawa MP, Marlicz W, Machalin´ski B. Complement system activation and endothelial dysfunction in patients with agerelated macular degeneration (AMD): possible rela- tionship between AMD and atherosclerosis. Acta Ophthalmol. 2012;90:695–703.
38. Klein R, Myers CE, Cruickshanks KJ, Gangnon RE, Danforth LG, Sivakumaran TA, et al. Markers of inflammation, oxida- tive stress, and endothelial dysfunction and the 20-year cumulative incidence of early age-related macular degeneration: the Beaver Dam Eye Study. JAMA Ophthalmol. 2014;132:446–55.
39. Machalin´ska A, Safranow K, Dziedziejko V, Mozolewska-Pio-trowska K, Paczkowska E, Klos P, et al. Different populations of circulating endothelial cells in patients with age-related macular degeneration: a novel insight into pathogenesis. Invest Ophthal- mol Vis Sci. 2011;52:93–100.
40. Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, et al. Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth fac- tor treatment: a retrospective cohort study Ophthalmology. 2015;122:2303–10.
41. Mantel I, Deli A, Iglesias K, Ambresin A. Prospective study evaluating the predictability of need for retreatment with intrav- itreal ranibizumab for agerelated macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013;251:697–704.
42. Kasahara K, Moriyama M, Morohoshi K et al (2017) Six-year outcomes of intravitreal bevacizumab for choroidal neovascularization in patients with pathologic myopia. Retina 37:1055-1064. https://doi.org/10.1097/IAE.0000000000001313
43. Kojima A, Ohno-Matsui K, Teramukai S et al (2004) Factors associated with the development of chorioretinal atrophy around choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 242:114-119. https://doi.org/10.1007/s00417-003-0803-9
44. Muakkassa NW, Chin AT, de Carlo TE et al (2015) Characterizing the effect of anti-vascular endothelial growth factor therapy on treatment-naïve choroidal neovascularization using optical coherence tomography angiography. Retina 35:2252-2259. https://doi.org/10.1097/IAE.0000000000000836
45. Lumbroso B, Rispoli M, Savastano MC (2015) Longitudinal optical coherence tomography-angiography study of type 2 naïve choroidal neovascularization early response after treatment. Retina 35:2242-2251. https://doi.org/10.1097/IAE.0000000000000879
46. Cheng Y, Li Y, Huang X, Qu Y (2019) Application of optical coherence tomography angiography to assess anti-vascular endothelial growth factor therapy in myopic choroidal neovascularization. Retina 39:712-718. https://doi.org/10.1097/IAE.0000000000002005
47. Lee JH, Lee SC, Kim SH et al (2017) Choroidal thickness and chorioretinal atrophy in myopic choroidal neovascularization with anti-vascular endothelial growth factor therapy. Retina 37:1516-1522. https://doi.org/10.1097/IAE.0000000000001384
48. Ahn SJ, Woo SJ, Kim KE et al (2013) Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization. Invest Ophthalmol Vis Sci 54:2115-2122. https://doi.org/10.1167/iovs.12-11542
49. Sayanagi K, Hara C, Wakabayashi T et al (2019) Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 257:749-757. https://doi.org/10.1007/s00417-018-04214-w
50. Hata M, Oishi A, Tsujikawa A et al (2014) Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability. Invest Ophthalmol Vis Sci 55:7874-7880. https://doi.org/10.1167/iovs.14-14610
51. Lois N, McBain V, Abdelkader E et al (2013) Retinal pigment epithelial atrophy in patients with exudative age-related macular degeneration undergoing antivascular endothelial growth factor therapy. Retina 33:13-22. https://doi.org/10.1097/IAE.0b013e3182657fff
52. Grunwald JE, Daniel E, Huang J et al (2014) Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121:150-161. https://doi.org/10.1016/j.ophtha.2013.08.015
53. Kuroda Y, Yamashiro K, Tsujikawa A et al (2016) Retinal pigment epithelial atrophy in neovascular age-related macular degeneration after ranibizumab treatment. Am J Ophthalmol 161:94-103.e1. https://doi.org/10.1016/j.ajo.2015.09.032
54. Cho HJ, Yoo SG, Kim HS et al (2015) Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. Am J Ophthalmol 159:285-292.e1. https://doi.org/10.1016/j.ajo.2014.10.035